Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2018 Jul 28

PMID 30052811

Citations 92

Authors

Huldrych F Gunthard

Vincent Calvez

Roger Paredes

Deenan Pillay

Robert W Shafer

Annemarie M Wensing

Donna M Jacobsen

Douglas D Richman

Affiliations

Soon will be listed here.

Abstract

Background: Contemporary antiretroviral therapies (ART) and management strategies have diminished both human immunodeficiency virus (HIV) treatment failure and the acquired resistance to drugs in resource-rich regions, but transmission of drug-resistant viruses has not similarly decreased. In low- and middle-income regions, ART roll-out has improved outcomes, but has resulted in increasing acquired and transmitted resistances. Our objective was to review resistance to ART drugs and methods to detect it, and to provide updated recommendations for testing and monitoring for drug resistance in HIV-infected individuals.

Methods: A volunteer panel of experts appointed by the International Antiviral (formerly AIDS) Society-USA reviewed relevant peer-reviewed data that were published or presented at scientific conferences. Recommendations were rated according to the strength of the recommendation and quality of the evidence, and reached by full panel consensus.

Results: Resistance testing remains a cornerstone of ART. It is recommended in newly-diagnosed individuals and in patients in whom ART has failed. Testing for transmitted integrase strand-transfer inhibitor resistance is currently not recommended, but this may change as more resistance emerges with widespread use. Sanger-based and next-generation sequencing approaches are each suited for genotypic testing. Testing for minority variants harboring drug resistance may only be considered if treatments depend on a first-generation nonnucleoside analogue reverse transcriptase inhibitor. Different HIV-1 subtypes do not need special considerations regarding resistance testing.

Conclusions: Testing for HIV drug resistance in drug-naive individuals and in patients in whom antiretroviral drugs are failing, and the appreciation of the role of testing, are crucial to the prevention and management of failure of ART.

Citing Articles

Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia.

Siegrist D, Jonsdottir H, Bouveret M, Boda B, Constant S, Engler O Pharmaceutics. 2024; 16(10).

PMID: 39458594 PMC: 11510096. DOI: 10.3390/pharmaceutics16101262.

Role of the pharmacist caring for people at risk of or living with HIV in Canada.

Tkachuk S, Ready E, Chan S, Hawkes J, Janzen Cheney T, Kapler J Can Pharm J (Ott). 2024; 157(5):218-239.

PMID: 39310805 PMC: 11412478. DOI: 10.1177/17151635241267350.

HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21.

Fabeni L, Armenia D, Abbate I, Gagliardini R, Mazzotta V, Bertoli A J Antimicrob Chemother. 2024; 79(9):2152-2162.

PMID: 39028674 PMC: 11368429. DOI: 10.1093/jac/dkae189.

Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.

Scholten S, Cahn P, Portilla J, Bisshop F, Hodder S, Ruane P Open Forum Infect Dis. 2024; 11(7):ofae365.

PMID: 39015350 PMC: 11250229. DOI: 10.1093/ofid/ofae365.

Prevalence of HIV Drug Resistance Mutations among Treatment-Naive People Living with HIV in a Tertiary Care Center in India.

Srivastva S, Chakravarty J, Kushwaha A Am J Trop Med Hyg. 2024; 110(4):713-718.

PMID: 38442417 PMC: 10993842. DOI: 10.4269/ajtmh.23-0026.

References

Lanier E, Ait-Khaled M, Scott J, Stone C, Melby T, Sturge G . Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther. 2004; 9(1):37-45. DOI: 10.1177/135965350400900102. View

Gonzalez-Serna A, Min J, Woods C, Chan D, Lima V, Montaner J . Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014; 58(8):1165-73. PMC: 3967823. DOI: 10.1093/cid/ciu019. View

Hirsch M, Conway B, DAquila R, Johnson V, Brun-Vezinet F, Clotet B . Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA. 1998; 279(24):1984-91. DOI: 10.1001/jama.279.24.1984. View

Rambaut A, Posada D, Crandall K, Holmes E . The causes and consequences of HIV evolution. Nat Rev Genet. 2004; 5(1):52-61. DOI: 10.1038/nrg1246. View

Santoro M, Fabeni L, Armenia D, Alteri C, Di Pinto D, Forbici F . Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis. 2014; 58(8):1156-64. DOI: 10.1093/cid/ciu020. View

Miller M, Margot N, Lu B, Zhong L, Chen S, Cheng A . Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004; 189(5):837-46. DOI: 10.1086/381784. View

Swenson L, Mo T, Dong W, Zhong X, Woods C, Jensen M . Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis. 2011; 203(2):237-45. PMC: 3071057. DOI: 10.1093/infdis/jiq030. View

Hofstra L, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D . Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. Clin Infect Dis. 2015; 62(5):655-663. PMC: 4741360. DOI: 10.1093/cid/civ963. View

King M, Rode R, Cohen-Codar I, Calvez V, Marcelin A, Hanna G . Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2007; 51(9):3067-74. PMC: 2043245. DOI: 10.1128/AAC.00388-07. View

10.

Revell A, Wang D, Wood R, Morrow C, Tempelman H, Hamers R . An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. J Antimicrob Chemother. 2016; 71(10):2928-37. PMC: 5031919. DOI: 10.1093/jac/dkw217. View

11.

Charpentier C, Camacho R, Ruelle J, Kaiser R, Eberle J, Gurtler L . HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin Infect Dis. 2013; 56(11):1654-8. DOI: 10.1093/cid/cit104. View

12.

Ryscavage P, Kelly S, Li J, Harrigan P, Taiwo B . Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014; 58(7):3585-98. PMC: 4068602. DOI: 10.1128/AAC.00076-14. View

13.

Scherrer A, Ledergerber B, von Wyl V, Boni J, Yerly S, Klimkait T . Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis. 2011; 53(11):1143-52. DOI: 10.1093/cid/cir669. View

14.

Swenson L, Min J, Woods C, Cai E, Li J, Montaner J . HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS. 2014; 28(8):1125-34. PMC: 4278403. DOI: 10.1097/QAD.0000000000000203. View

15.

Rieder P, Joos B, Scherrer A, Kuster H, Braun D, Grube C . Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clin Infect Dis. 2011; 53(12):1271-9. DOI: 10.1093/cid/cir725. View

16.

Haggblom A, Svedhem V, Singh K, Sonnerborg A, Neogi U . Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden. Lancet HIV. 2016; 3(4):e166-74. PMC: 5492226. DOI: 10.1016/S2352-3018(16)00023-0. View

17.

Hauser A, Hofmann A, Hanke K, Bremer V, Bartmeyer B, Kuecherer C . National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014. Euro Surveill. 2017; 22(2). PMC: 5404484. DOI: 10.2807/1560-7917.ES.2017.22.2.30436. View

18.

Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I . Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med. 2016; 18(3):204-213. PMC: 5297994. DOI: 10.1111/hiv.12414. View

19.

Hamers R, Wallis C, Kityo C, Siwale M, Mandaliya K, Conradie F . HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011; 11(10):750-9. DOI: 10.1016/S1473-3099(11)70149-9. View

20.

Lundgren J, Babiker A, Gordin F, Emery S, Grund B, Sharma S . Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373(9):795-807. PMC: 4569751. DOI: 10.1056/NEJMoa1506816. View